Lexicon Pharmaceuticals Company Profile (NASDAQ:LXRX)

Lexicon Pharmaceuticals trades on the NASDAQ under the ticker symbol "LXRX."

Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) posted its earnings results on Thursday, August, 4th. The company reported ($0.37) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.40) by $0.03. The company earned $20.10 million during the quarter, compared to analysts' expectations of $12.36 million. Lexicon Pharmaceuticals had a negative return on equity of 81.46% and a negative net margin of 158.68%. The firm's quarterly revenue was up 5186.8% compared to the same quarter last year. During the same quarter last year, the firm earned ($0.27) earnings per share. View Lexicon Pharmaceuticals' Earnings History.

Lexicon Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Wednesday, August, 2nd 2017. View Earnings Estimates for Lexicon Pharmaceuticals.

6 brokers have issued 1 year price targets for Lexicon Pharmaceuticals' shares. Their predictions range from $21.00 to $38.00. On average, they anticipate Lexicon Pharmaceuticals' share price to reach $28.00 in the next year. View Analyst Ratings for Lexicon Pharmaceuticals.

Here are some recent quotes from research analysts about Lexicon Pharmaceuticals stock:

• 1. According to Zacks Investment Research, "Lexicon Genetics Incorporated is a leader in defining the functions of genes for drug discovery using large-scale knockout mouse technology. Lexicon has invented high-throughput gene trapping technology to discover thousands of genes and expand its OmniBank library of tens of thousands of mouse clones. The Company uses an integrated platform of functional genomic technologies to accelerate large-scale analysis of mammalian gene function for drug discovery. " (7/18/2017)
• 2. Wedbush analysts commented, "Even with FDA approval of LXRX's lead drug achieved, we still see several clinical and regulatory catalysts for LXRX over the coming months that could lift shares."In addition to the launch of XERMELO, we see several catalysts for LXRX, including data presentations of the InTandem 1&2 results at ADA (June 9-13, San Diego), release of 52-week pivotal extension results from InTandem 1, 2 and 3 in Mid:17, and potential early indication that the FDA may consider reviewing sotagliflozin for T1D alone in Q3:17," (3/1/2017)
• 3. Needham & Company LLC analysts commented, "Lexicon and FDA announced approval of Xermelo (telotristat) yesterday for treatment of Carcinoid Syndrome. Label appears favorable w/ no contraindications and only constipation as a warning/ precaution. Mgmt guided for availability at specialty pharmacies 3/6/17. WAC pricing set at $5,164/ 28 days (~67,000/ yr), in-line w/ prior mgmt guidance (i.e. comparable to somatostatin analogs). We estimate U.S. peak sales ~$300M (unch). Pt population is well defined due to availability of somatostatin analogs and we believe Lexicon can penetrate market reasonably quickly. Lexicon hired ~50 sales reps, consistent w/ prior guidance. They will begin visiting physicians 3/2/17. Near-term milestones for Lexicon include update on sotagliflozin NDA submission strategy/ timing in Type 1 Diabetes. We assume YE17. Reiterate BUY." (3/1/2017)

Some companies that are related to Lexicon Pharmaceuticals include Intercept Pharmaceuticals (ICPT), Juno Therapeutics (JUNO), Ultragenyx Pharmaceutical (RARE), GW Pharmaceuticals PLC (GWPH), BeiGene (BGNE), Agios Pharmaceuticals (AGIO), China Biologic Products (CBPO), AveXis (AVXS), Prothena Corporation PLC (PRTA), Axovant Sciences (AXON), Sarepta Therapeutics (SRPT), Spark Therapeutics (ONCE), Loxo Oncology (LOXO), Radius Health (RDUS), Aerie Pharmaceuticals (AERI), Halozyme Therapeutics (HALO), NovoCure Limited (NVCR) and Array BioPharma (ARRY).

Lexicon Pharmaceuticals' management team includes the folowing people:

• Raymond Debbane, Independent Chairman of the Board
• Lonnel Coats, President, Chief Executive Officer, Director
• Jeffrey L. Wade J.D., Chief Financial Officer, Executive Vice President - Corporate and Administrative Affairs
• Pablo Lapuerta M.D., Executive Vice President, Chief Medical Officer
• Alan J. Main Ph.D., Executive Vice President - CMC and Supply Operations
• Alexander A. Santini, Executive Vice President, Chief Commercial Officer
• Praveen Tyle Ph.D., Executive Vice President - Research and Development
• James F. Tessmer, Vice President - Finance & Accounting
• Philippe J. Amouyal, Independent Director
• Samuel L. Barker Ph.D., Independent Director

Lexicon Pharmaceuticals' stock is owned by many different of institutional and retail investors. Top institutional shareholders include NEA Management Company LLC (2.26%), Russell Investments Group Ltd. (0.07%), Bank of Montreal Can (0.06%), Boston Advisors LLC (0.03%), Round Table Services LLC (0.02%) and Public Employees Retirement Association of Colorado (0.01%). View Institutional Ownership Trends for Lexicon Pharmaceuticals.

Lexicon Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including Bank of Montreal Can, Boston Advisors LLC and Russell Investments Group Ltd.. View Insider Buying and Selling for Lexicon Pharmaceuticals.

Shares of Lexicon Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of Lexicon Pharmaceuticals stock can currently be purchased for approximately $16.87.